These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 23401595

  • 1. Paracaspase MALT1 deficiency protects mice from autoimmune-mediated demyelination.
    Mc Guire C, Wieghofer P, Elton L, Muylaert D, Prinz M, Beyaert R, van Loo G.
    J Immunol; 2013 Mar 15; 190(6):2896-903. PubMed ID: 23401595
    [Abstract] [Full Text] [Related]

  • 2. Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation.
    Bornancin F, Renner F, Touil R, Sic H, Kolb Y, Touil-Allaoui I, Rush JS, Smith PA, Bigaud M, Junker-Walker U, Burkhart C, Dawson J, Niwa S, Katopodis A, Nuesslein-Hildesheim B, Weckbecker G, Zenke G, Kinzel B, Traggiai E, Brenner D, Brüstle A, St Paul M, Zamurovic N, McCoy KD, Rolink A, Régnier CH, Mak TW, Ohashi PS, Patel DD, Calzascia T.
    J Immunol; 2015 Apr 15; 194(8):3723-34. PubMed ID: 25762782
    [Abstract] [Full Text] [Related]

  • 3. The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.
    Brüstle A, Brenner D, Knobbe CB, Lang PA, Virtanen C, Hershenfield BM, Reardon C, Lacher SM, Ruland J, Ohashi PS, Mak TW.
    J Clin Invest; 2012 Dec 15; 122(12):4698-709. PubMed ID: 23114599
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis.
    Mc Guire C, Elton L, Wieghofer P, Staal J, Voet S, Demeyer A, Nagel D, Krappmann D, Prinz M, Beyaert R, van Loo G.
    J Neuroinflammation; 2014 Jul 21; 11():124. PubMed ID: 25043939
    [Abstract] [Full Text] [Related]

  • 6. Uncoupling Malt1 threshold function from paracaspase activity results in destructive autoimmune inflammation.
    Gewies A, Gorka O, Bergmann H, Pechloff K, Petermann F, Jeltsch KM, Rudelius M, Kriegsmann M, Weichert W, Horsch M, Beckers J, Wurst W, Heikenwalder M, Korn T, Heissmeyer V, Ruland J.
    Cell Rep; 2014 Nov 20; 9(4):1292-305. PubMed ID: 25456129
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The innate immune adaptor MyD88 is dispensable for spontaneous autoimmune demyelination in a mouse model of multiple sclerosis.
    Wexler AG, Frielle C, Berry G, Budgeon LR, Baccon J, Christensen ND, Waldner H.
    J Neuroimmunol; 2013 Feb 15; 255(1-2):60-9. PubMed ID: 23269203
    [Abstract] [Full Text] [Related]

  • 9. MALT1--a universal soldier: multiple strategies to ensure NF-κB activation and target gene expression.
    Afonina IS, Elton L, Carpentier I, Beyaert R.
    FEBS J; 2015 Sep 15; 282(17):3286-97. PubMed ID: 25996250
    [Abstract] [Full Text] [Related]

  • 10. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20.
    Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J, Sun L, Chen ZJ, Marynen P, Beyaert R.
    Nat Immunol; 2008 Mar 15; 9(3):263-71. PubMed ID: 18223652
    [Abstract] [Full Text] [Related]

  • 11. The Paracaspase MALT1.
    Hachmann J, Salvesen GS.
    Biochimie; 2016 Mar 15; 122():324-38. PubMed ID: 26386283
    [Abstract] [Full Text] [Related]

  • 12. Oligodendrocyte-specific FADD deletion protects mice from autoimmune-mediated demyelination.
    Mc Guire C, Volckaert T, Wolke U, Sze M, de Rycke R, Waisman A, Prinz M, Beyaert R, Pasparakis M, van Loo G.
    J Immunol; 2010 Dec 15; 185(12):7646-53. PubMed ID: 21068410
    [Abstract] [Full Text] [Related]

  • 13. Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
    Shaw MA, Gao Z, McElhinney KE, Thornton S, Flick MJ, Lane A, Degen JL, Ryu JK, Akassoglou K, Mullins ES.
    J Neurosci; 2017 Apr 05; 37(14):3776-3788. PubMed ID: 28275164
    [Abstract] [Full Text] [Related]

  • 14. Targeting MALT1 Proteolytic Activity in Immunity, Inflammation and Disease: Good or Bad?
    Demeyer A, Staal J, Beyaert R.
    Trends Mol Med; 2016 Feb 05; 22(2):135-150. PubMed ID: 26787500
    [Abstract] [Full Text] [Related]

  • 15. MALT1 Proteolytic Activity Suppresses Autoimmunity in a T Cell Intrinsic Manner.
    Demeyer A, Skordos I, Driege Y, Kreike M, Hochepied T, Baens M, Staal J, Beyaert R.
    Front Immunol; 2019 Feb 05; 10():1898. PubMed ID: 31474984
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. IL-7/IL-7 Receptor Signaling Differentially Affects Effector CD4+ T Cell Subsets Involved in Experimental Autoimmune Encephalomyelitis.
    Arbelaez CA, Glatigny S, Duhen R, Eberl G, Oukka M, Bettelli E.
    J Immunol; 2015 Sep 01; 195(5):1974-83. PubMed ID: 26223651
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cytosolic phospholipase A2α blockade abrogates disease during the tissue-damage effector phase of experimental autoimmune encephalomyelitis by its action on APCs.
    Thakker P, Marusic S, Stedman NL, Lee KL, McKew JC, Wood A, Goldman SJ, Leach MW, Collins M, Kuchroo VK, Wolf SF, Clark JD, Hassan-Zahraee M.
    J Immunol; 2011 Aug 15; 187(4):1986-97. PubMed ID: 21746963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.